Deutsche Bank AG Sells 14,242 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Key Points

• Deutsche Bank AG reduced its stake in ANI Pharmaceuticals by 6.1%, selling 14,242 shares, leaving it with 218,086 shares worth approximately $14.6 million.
• Insider selling included CFO Stephen P. Carey and CEO Nikhil Lalwani, who sold 50,000 and 56,960 shares respectively, indicating significant decreases in their ownership positions.
• ANI Pharmaceuticals reported strong earnings with $1.80 EPS for the last quarter, exceeding estimates, and experienced a 53.2% year-over-year revenue increase to $211.37 million.

Deutsche Bank AG reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 218,086 shares of the specialty pharmaceutical company's stock after selling 14,242 shares during the quarter. Deutsche Bank AG owned approximately 1.00% of ANI Pharmaceuticals worth $14,601,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANIP. Geode Capital Management LLC increased its position in ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after acquiring an additional 3,774 shares during the period. Wells Fargo & Company MN increased its position in shares of ANI Pharmaceuticals by 35.7% during the fourth quarter. Wells Fargo & Company MN now owns 10,169 shares of the specialty pharmaceutical company's stock worth $562,000 after buying an additional 2,676 shares during the period. Envestnet Asset Management Inc. increased its position in shares of ANI Pharmaceuticals by 34.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 4,930 shares of the specialty pharmaceutical company's stock worth $273,000 after buying an additional 1,256 shares during the period. Legal & General Group Plc increased its position in shares of ANI Pharmaceuticals by 5.6% during the fourth quarter. Legal & General Group Plc now owns 48,425 shares of the specialty pharmaceutical company's stock worth $2,677,000 after buying an additional 2,585 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $3,916,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,975 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $85.71, for a total value of $426,407.25. Following the transaction, the senior vice president directly owned 40,794 shares of the company's stock, valued at approximately $3,496,453.74. This trade represents a 10.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nikhil Lalwani sold 56,960 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $85.93, for a total transaction of $4,894,572.80. Following the completion of the transaction, the chief executive officer directly owned 411,219 shares in the company, valued at $35,336,048.67. This trade represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 138,349 shares of company stock valued at $11,880,691. Corporate insiders own 11.10% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ANIP. HC Wainwright reiterated a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Piper Sandler reiterated an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. Finally, Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $84.75.

ANI Pharmaceuticals Stock Down 2.8%

NASDAQ ANIP traded down $2.53 on Friday, hitting $87.47. 1,063,485 shares of the company were exchanged, compared to its average volume of 633,874. The company has a market cap of $1.90 billion, a PE ratio of -113.60 and a beta of 0.61. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $90.23. The stock has a fifty day moving average of $67.85 and a 200-day moving average of $64.86. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period last year, the firm earned $1.02 earnings per share. The business's quarterly revenue was up 53.2% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.